185 related articles for article (PubMed ID: 7473469)
21. The association between malignant melanoma and noncutaneous malignancies.
Wu YH; Kim GH; Wagner JD; Hood AF; Chuang TY
Int J Dermatol; 2006 May; 45(5):529-34. PubMed ID: 16700785
[TBL] [Abstract][Full Text] [Related]
22. The age-risk relationship of haematologic malignancies in female patients with systemic lupus erythematosus: a nationwide retrospective cohort study.
Lin YC; Yen JH; Chang SJ; Lin YC
Lupus; 2012 Oct; 21(11):1250-6. PubMed ID: 22740427
[TBL] [Abstract][Full Text] [Related]
23. Risk of primary non-hepatocellular malignancies in hereditary hemochromatosis.
Geier D; Hebert B; Potti A
Anticancer Res; 2002; 22(6B):3797-9. PubMed ID: 12552996
[TBL] [Abstract][Full Text] [Related]
24. Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus.
Mok CC; Ho LY; To CH
Scand J Rheumatol; 2009; 38(5):362-8. PubMed ID: 19296403
[TBL] [Abstract][Full Text] [Related]
25. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
[TBL] [Abstract][Full Text] [Related]
26. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors.
Urowitz MB; Ibañez D; Gladman DD
J Rheumatol; 2007 Jan; 34(1):70-5. PubMed ID: 17117488
[TBL] [Abstract][Full Text] [Related]
27. Occupation and cancer - follow-up of 15 million people in five Nordic countries.
Pukkala E; Martinsen JI; Lynge E; Gunnarsdottir HK; Sparén P; Tryggvadottir L; Weiderpass E; Kjaerheim K
Acta Oncol; 2009; 48(5):646-790. PubMed ID: 19925375
[TBL] [Abstract][Full Text] [Related]
28. The characteristics of systemic lupus erythematosus. A study in a general hospital.
Karadsheh MF; Nimri FA; Ajlouni YM; Dneibat WA; Karadsheh RF
Saudi Med J; 2000 Mar; 21(3):282-6. PubMed ID: 11533799
[TBL] [Abstract][Full Text] [Related]
29. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort.
Petri M; Genovese M
J Rheumatol; 1992 Oct; 19(10):1559-65. PubMed ID: 1464868
[TBL] [Abstract][Full Text] [Related]
30. The risk of ano-genital malignancies in dialysis and transplant patients.
Fairley CK; Sheil AG; McNeil JJ; Ugoni AM; Disney AP; Giles GG; Amiss N
Clin Nephrol; 1994 Feb; 41(2):101-5. PubMed ID: 8004825
[TBL] [Abstract][Full Text] [Related]
31. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
32. Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers.
Löfström B; Backlin C; Sundström C; Hellström-Lindberg E; Ekbom A; Lundberg IE
Rheumatology (Oxford); 2009 Oct; 48(10):1222-6. PubMed ID: 19608725
[TBL] [Abstract][Full Text] [Related]
33. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
Mok MY; Lo Y; Chan TM; Wong WS; Lau CS
J Rheumatol; 2005 Apr; 32(4):609-15. PubMed ID: 15801014
[TBL] [Abstract][Full Text] [Related]
34. [Renal graft survival in patients with systemic lupus erythematosus].
Chew-Wong A; Soltero L; Diná E; Alvarez-Sandoval E; Alberú J; Gamba G; Correa-Rotter R
Rev Invest Clin; 2002; 54(1):21-8. PubMed ID: 11995403
[TBL] [Abstract][Full Text] [Related]
35. Lung cancer in systemic lupus erythematosus.
Bin J; Bernatsky S; Gordon C; Boivin JF; Ginzler E; Gladman D; Fortin PR; Urowitz M; Manzi S; Isenberg D; Rahman A; Petri M; Nived O; Sturfeldt G; Ramsey-Goldman R; Clarke AE
Lung Cancer; 2007 Jun; 56(3):303-6. PubMed ID: 17291624
[TBL] [Abstract][Full Text] [Related]
36. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study.
Cooper GS; Dooley MA; Treadwell EL; St Clair EW; Gilkeson GS
Arthritis Rheum; 2002 Jul; 46(7):1830-9. PubMed ID: 12124867
[TBL] [Abstract][Full Text] [Related]
37. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy.
Bruce IN; Hallett DC; Gladman DD; Urowitz MB
J Rheumatol; 1999 Jul; 26(7):1490-4. PubMed ID: 10405935
[TBL] [Abstract][Full Text] [Related]
38. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
McLaurin EY; Holliday SL; Williams P; Brey RL
Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
[TBL] [Abstract][Full Text] [Related]
39. Malignancy and autoimmunity.
Bernatsky S; Ramsey-Goldman R; Clarke A
Curr Opin Rheumatol; 2006 Mar; 18(2):129-34. PubMed ID: 16462517
[TBL] [Abstract][Full Text] [Related]
40. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Brown JR; Yeckes H; Friedberg JW; Neuberg D; Kim H; Nadler LM; Freedman AS
J Clin Oncol; 2005 Apr; 23(10):2208-14. PubMed ID: 15753460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
